GlaxoSmithKline’s potential first-in-class multiple myeloma drug belantamab mafodotin has taken a step closer to US approval after unanimous backing from a panel of expert advisers convened
OPEN Health’s Christine Drewienkiewicz, Sara Black and Annie Rankin on advances in modern oncology and how pharma can help ensure maximum patient benefit
Amgen has scored yet another home run in the US courts, this time seeing off a legal challenge from Genentech, which was trying to block it from launching two cut-price cancer biosimilars.
The FDA has approved Pfizer and Merck KGaA’s immunotherapy Bavencio (avelumab) as a first line maintenance therapy in bladder cancer, setting up a rivalry with alternatives from Roche and A